Shamburg News · 8-K filed Nov 5, 2026, 7:13 AM EST
Akebia Therapeutics Reports Third Quarter 2026 Results; Net Loss of $14.4 Million
AKBA · Akebia Therapeutics, Inc.
- Earnings
- Materiality: high
Akebia Therapeutics reported a net loss of $14.4 million for the third quarter ended September 30, 2026, compared with net income of $0.5 million a year earlier. Total revenues were $36.9 million versus $58.8 million, with Vafseo net product revenues of $14.8 million and Auryxia net product revenues of $20.0 million. Cash and cash equivalents were approximately $159.3 million at quarter end. The results were furnished under Item 2.02 via press release dated November 5, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001517022-26-000083.
Written from the filing by Shamburg Markets. Figures are as reported by the company.